Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 151

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 151
---

naturally decays into the Radium-224 that is collected onto the sources. We acquire Thorium-228 from the Oak Ridge National Laboratory
of the United States Department of Energy. We are also aware of or have spoken with other potential suppliers of Thorium-228, such that
we anticipate steady supply of thorium for the production of the Alpha DaRT, although we note the increased demand for Thorium-228 and
its daughter atoms in light of the increasing interest in exploring the use of Lead-212 in systemic radiopharmaceuticals.

We currently operate two manufacturing
plants. One, located in Jerusalem, Israel, is currently operational and ramping up to full capacity, and contains sufficient capacity
for approximately 200,000 sources for local use at current capacity. Our second facility, in Lawrence, Massachusetts, was completed in
2020 and began producing Thorium-228 generators at the start of 2021. In July 2023, we were awarded a discounted long-term leasehold from
the Israel Land Authority on a plot of land of approximately 6,660 square meters (1.65 acres) in the Har Hotzvim Industrial Park in Jerusalem,
near the Company’s current headquarters leased in an existing facility in the same park, where we expect to develop the land toward
a future standalone global headquarters and lead manufacturing site, including significantly expanded areas for Alpha DaRT manufacturing,
staff, and R& D facilities. In October 2023 we entered into a long-term lease agreement for a standalone building of over 14,000 rentable
square feet in Hudson, New Hampshire, where we are currently constructing our second U. S. manufacturing site, which will be focused on
the manufacturing of Alpha DaRT sources in the U. S. Construction is currently underway, with a total expected capacity of approximately
400,000 sources for local use from the first phase when at full capacity, and we expect the first phase to be ready for production by
the end of 2025. We have also entered into a lease for a building in Togane, Japan where we are exploring a potential facility of a similar
size as our current Jerusalem facility at scale. The modular nature of our manufacturing capacity allows us to initiate manufacturing
more swiftly and then scale up to full capacity over time. We believe these facilities will enable us to maintain sufficient quantities
of Thorium-228 securely, to safely produce and capture radium from thorium’s alpha decay, to affix the radium onto